| Project/Area Number |
17K08665
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | がん / 接着分子 / インテグリン / 抗がん薬耐性 / β4インテグリン / 癌 / 薬剤耐性 / 分子腫瘍学 |
|---|
| Outline of Final Research Achievements |
In this study, we clarified that one of the protein, beta4 integrin, is associated with chemoresistance of cancer cells. The cancer cells expressing beta4 integrin showed more resistant against anti-cancer drug compared to the cancer cells without beta4 integrin expression. We also demonstrated that beta4 integrin signaling is participated in beta4 integrin-inducing anti-cancer drug resistance. Moreover, anti-caner drug resistant cancer cells with high beta4 integrin expression promoted cancer cell invasion, and tumorigenesis. These results suggest that beta4 integrin is an important protein for preparing the drug against the cancer cells with chemoresistance.
|
| Academic Significance and Societal Importance of the Research Achievements |
がんは国民の2人に1人は一生のうちにかかるといわれており、長い間日本における死因第一位となっています。そうしたがんを克服するためには転移を抑えることに加え、抗がん薬の耐性化を防ぐことが重要です。本研究ではβ4インテグリンというタンパク質ががんの薬剤耐性化に関わっていることを明らかにしました。将来、β4インテグリンを抑えるような薬を作ればがんの薬剤耐性を防ぐことが可能になるかもしれません。
|
